Clinical Characteristics and Prognosis Analysis of Acinetobacter baumannii Bloodstream Infection Based on Propensity Matching

References

• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951. doi:10.1038/nrmicro1789
   PubMed Web of Science ®Google Scholar
• Ashuthosh KC, Hegde A, Rao P, Manipura R. Multidrug-resistant Acinetobacter baumannii - the modern menace: a retrospective study in a tertiary hospital in Mangalore. Infect Drug Resist. 2020;13:2181–2187. doi:10.2147/IDR.S249123
   Web of Science ®Google Scholar
• Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48(10):6987–6998. doi:10.1007/s11033-021-06690-6
   PubMed Web of Science ®Google Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249–1260. doi:10.2147/IDR.S166750
   PubMed Web of Science ®Google Scholar
• Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study. Intensive Care Med. 2012;38(12):1930–1945. doi:10.1007/s00134-012-2695-9
   PubMed Web of Science ®Google Scholar
• Change in antimicrobial resistance of pathogens from blood specimens: surveillance report from China Antimicrobial resistance surveillance system in 2014–2019. Chin J Infect Control. 2021;20(02):124–133.
   Google Scholar
• Townsend J, Park AN, Gander R, et al. Acinetobacter infections and outcomes at an academic medical center: a disease of long-term care. Open Forum Infect Dis. 2015;2(1):ofv023. doi:10.1093/ofid/ofv023
   PubMed Web of Science ®Google Scholar
• Leao AC, Menezes PR, Oliveira MS, Levin AS. Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. BMC Infect Dis. 2016;16:386. doi:10.1186/s12879-016-1695-8
   PubMed Web of Science ®Google Scholar
• Gu Z, Han Y, Meng T, et al. Risk factors and clinical outcomes for patients with Acinetobacter baumannii bacteremia. Medicine. 2016;95(9):e2943. doi:10.1097/MD.0000000000002943
   Web of Science ®Google Scholar
• Ballouz T, Aridi J, Afif C, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol. 2017;7:156. doi:10.3389/fcimb.2017.00156
   PubMed Web of Science ®Google Scholar
• Kim T, Lee EJ, Park SY, et al. Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: a retrospective multicenter study in Korea. Medicine. 2018;97(43):e12984. doi:10.1097/MD.0000000000012984
   Web of Science ®Google Scholar
• Son HJ, Cho EB, Bae M, et al. Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Open Forum Infect Dis. 2020;7(10):ofaa378. doi:10.1093/ofid/ofaa378
   Web of Science ®Google Scholar
• Amoah J, Stuart EA, Cosgrove SE, et al. Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. Clin Infect Dis. 2020;71(9):e497–e505. doi:10.1093/cid/ciaa169
   Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.002
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Zone diameter breakpoints for rapid antimicrobial susceptibility testing (RAST) directly from blood culture bottles. Version 4.0; 2022. Available from: http://www.eucast.org. Accessed November 23, 2022.
   Google Scholar
• Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013;19(6):501–509. doi:10.1111/1469-0691.12195
   PubMed Web of Science ®Google Scholar
• Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect. 2008;56(1):27–34. doi:10.1016/j.jinf.2007.10.001
   Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138. doi:10.1016/j.jinf.2019.05.017
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48. doi:10.1186/cc4869
   PubMed Web of Science ®Google Scholar
• Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140–1145. doi:10.1016/j.ajic.2019.03.003
   PubMed Web of Science ®Google Scholar
• Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R. The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-net data from 2013 to 2017. Antimicrob Resist Infect Control. 2020;9(1):89. doi:10.1186/s13756-020-00750-5
   PubMed Web of Science ®Google Scholar
• Giammanco A, Cala C, Fasciana T, Dowzicky MJ, Bradford PA. Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. mSphere. 2017;2(1). doi:10.1128/mSphere.00310-16
   Web of Science ®Google Scholar
• Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis. 2002;34(12):1600–1606. doi:10.1086/340616
   PubMed Web of Science ®Google Scholar
• Liu Q, Li W, Du X, et al. Risk and prognostic factors for multidrug-resistant Acinetobacter Baumannii complex bacteremia: a retrospective study in a tertiary hospital of West China. PLoS One. 2015;10(6):e0130701. doi:10.1371/journal.pone.0130701
   Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ, Castanheira M. Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial surveillance program (2012–2017). Diagn Microbiol Infect Dis. 2020;97(2):115016. doi:10.1016/j.diagmicrobio.2020.115016
   PubMed Web of Science ®Google Scholar
• Santoro A, Franceschini E, Meschiari M, et al. Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria. Open Forum Infect Dis. 2020;7(11):ofaa461. doi:10.1093/ofid/ofaa461
   PubMed Web of Science ®Google Scholar
• Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med. 2009;20(5):540–544. doi:10.1016/j.ejim.2009.05.005
   PubMed Web of Science ®Google Scholar
• McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45(3):329–337. doi:10.1086/519283
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• Kadri SS, Lai YL, Warner S, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241–251. doi:10.1016/S1473-3099(20)30477-1
   PubMed Web of Science ®Google Scholar
• Lodise TP, Kanakamedala H, Hsu WC, Cai B. Impact of incremental delays in appropriate therapy on the outcomes of hospitalized adult patients with gram-negative bloodstream infections: “every day matters”. Pharmacotherapy. 2020;40(9):889–901. doi:10.1002/phar.2446
   Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P, Kasatpibal N. Effectiveness and nephrotoxicity of loading dose colistin-meropenem versus loading dose colistin-imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection. Pharmaceutics. 2022;14(6):1266.
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Short-course versus long-course colistin for treatment of carbapenem-resistant A.baumannii in cancer patient. Antibiotics. 2021;10(5):484. doi:10.3390/antibiotics10050484
   Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America guidance on the treatment of ampC beta-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. doi:10.1093/cid/ciab1013
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/S1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2):162.
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10):647. doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Digiovine BCC, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med. 1999;160:976–981. doi:10.1164/ajrccm.160.3.9808145
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chao TF, Chiang MC, et al. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern Med. 2011;50(8):871–877. doi:10.2169/internalmedicine.50.4312
   Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Fligou F, Spiliopoulou A, et al. Risk factors and predictors of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii mortality in critically ill bacteraemic patients over a 6-year period (2010-15): antibiotics do matter. J Med Microbiol. 2017;66(8):1092–1101. doi:10.1099/jmm.0.000538
   Web of Science ®Google Scholar
• Niu T, Xiao T, Guo L, et al. Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality. Infect Drug Resist. 2018;11:2021–2030. doi:10.2147/IDR.S169432
   PubMed Web of Science ®Google Scholar